Investing Investment Strategy

  • Vanguard Founder: Market's Next Move

    Vanguard founder John Bogle looks at valuations, speculation and stocks vs. bonds. The biggest risk for investors, with CNBC's Mandy Drury and the Futures Now Traders, Jim Iourio at the CME and Anthony Grisanti at the Nymex.

  • FMHR Final Trade

    The FMHR traders reveal their final trades.

  • You Tweet It, We Trade It!

    The FMHR traders discuss how to play Google, Goldman Sachs, and other stocks requested on Twitter.

  • A U.S. energy revolution is underway as the country takes advantage of its abundant natural gas supplies. Here are some investment ideas.

  • What's Driving the Dollar?

    The U.S. dollar is moving down today. How to play the currency, with Paul Richards of UBS.

  • Are Stocks Still Cheap?

    Dissecting today's market action in the European markets, with CNBC's Simon Hobbs; and weighing in on activists role in the markets and whether stocks are still cheap is Aswath Damodaran, NYU Professor.

  • Damodaran's Market 'Sweet Spot' Worries

    Valuations have put the stock market in a "sweet spot," but one factor could sour it, says NYU finance professor Aswath Damodaran.

  • Top 3 Trades: BlackBerry, Best Buy & VeriFone

    VeriFone's CEO is stepping down, and the stock is going up, with the FMHR traders.

  • Futures Now: Time to Buy Gold?

    The Futures Now team discusses whether it is finally time to buy gold on the strength in the Japanese yen.

  • R. Allen Stanford

    Investors in Allen Stanford's $7 billion Ponzi scheme, who have recovered nothing in the four years since it blew up, could finally get some money back under a $300 million multi-national settlement in the case.

  • Merck Shares Spike

    The FMHR traders debate how to play Yum! Brands after the company's China sales fell less-than-expected; and Steve Grasso of Stuart Frankel offers his opinion on whether Merck has more upside ahead.

  • TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.

  • The Next Leg of the Rally

    Discussing which stocks will lead the rally's next leg, with Bob Doll, Nuveen Asset Management and the FMHR traders.

  • Kaminsky's Farewell Op-Ed

    A look back at some of Gary Kaminsky's most memorable moments at CNBC, as he shares his final views on the future of interest rates and the biggest issues facing investors now.

  • 90 Seconds with Art Cashin: Markets Ready For a Break

    In his daily CNBC.com-only video clip, Art Cashin of UBS talks with Bob Pisani about why it looks like the stock market rally will pause soon. (1:52)

  • More Highs Ahead For Dow?

    Russ Koesterich, BlackRock, tells investors how to play the record rally.

  • The brightening U.S. economy is lifting the dollar, but this expert says certain dollar trades will do better than others. Hint: look for central bank stimulus.

  • Santelli Explores High Frequency Trading

    CNBC's Rick Santelli takes a look at a Harvard paper that suggests HFT removes liquidity in the markets.

  • General Electric has made tremendous progress over the past few years and the increase in the company's share price has led to a downgrade by Nomura Securities analyst.

  • Market Pullback or Rally On?

    Harry Clark, Clark Capital Management founder, president & CEO, weighs in on whether investors should buy on the dips and provides his top stock picks.